Total Payments
$563,203
2024 Payments
$77.16
Companies
26
Transactions
338
Medicare Patients
2,510
Medicare Billing
$188,836
Payment Breakdown by Category
Research$560,424 (99.5%)
Food & Beverage$1,693 (0.3%)
Consulting$1,054 (0.2%)
Education$32.82 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $560,424 | 254 | 99.5% |
| Food and Beverage | $1,693 | 78 | 0.3% |
| Consulting Fee | $1,054 | 2 | 0.2% |
| Education | $32.82 | 4 | 0.0% |
Payments by Type
Research
$560,424
254 transactions
General
$2,780
84 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GRT US Holding, Inc. | $257,402 | 5 | $0 (2019) |
| Astellas Pharma Global Development | $143,310 | 7 | $0 (2019) |
| Daiichi Sankyo Inc. | $94,729 | 220 | $0 (2018) |
| Collegium Pharmaceutical, Inc. | $50,088 | 6 | $0 (2020) |
| Purdue Pharma L.P. | $5,627 | 6 | $0 (2020) |
| Egalet US Inc | $4,881 | 5 | $0 (2018) |
| West-Ward Pharmaceuticals | $4,060 | 5 | $0 (2018) |
| Hikma Pharmaceuticals USA | $996.58 | 1 | $0 (2020) |
| Endo Pharmaceuticals Inc. | $383.73 | 1 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $377.33 | 21 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $77.16 | 3 | Lilly USA, LLC ($52.25) |
| 2023 | $186.55 | 7 | AstraZeneca Pharmaceuticals LP ($45.55) |
| 2022 | $145.65 | 7 | Amgen Inc. ($34.55) |
| 2021 | $303.96 | 13 | Janssen Pharmaceuticals, Inc ($70.85) |
| 2020 | $2,130 | 7 | Hikma Pharmaceuticals USA ($996.58) |
| 2019 | $266,783 | 15 | GRT US Holding, Inc. ($257,402) |
| 2018 | $205,550 | 43 | Astellas Pharma Global Development ($134,110) |
| 2017 | $88,028 | 243 | Daiichi Sankyo Inc. ($84,834) |
All Payment Transactions
338 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/06/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.91 | General |
| 06/06/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $32.28 | General |
| Category: Diabetes | ||||||
| 04/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: Diabetes | ||||||
| 12/07/2023 | Kiniksa Pharmaceuticals, Ltd. | Arcalyst (Drug) | Food and Beverage | Cash or cash equivalent | $27.67 | General |
| Category: Not Applicable | ||||||
| 11/09/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $27.80 | General |
| Category: Diabetes | ||||||
| 10/26/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE, SYNJARDY | Food and Beverage | In-kind items and services | $30.24 | General |
| Category: DIABETES | ||||||
| 10/06/2023 | Shield Therapeutics Inc | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $31.85 | General |
| Category: Hematology | ||||||
| 08/22/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.33 | General |
| 06/20/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/16/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: Cardio-renal | ||||||
| 10/20/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $26.55 | General |
| Category: Diabetes | ||||||
| 07/22/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: Cardiology | ||||||
| 07/19/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: NEUROSCIENCE | ||||||
| 06/24/2022 | Amgen Inc. | — | Education | In-kind items and services | $13.89 | General |
| 06/09/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $19.72 | General |
| Category: Cardiovascular | ||||||
| 03/10/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Respiratory | ||||||
| 02/17/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: DIABETES | ||||||
| 11/15/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $34.71 | General |
| Category: DIABETES | ||||||
| 10/25/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: Cardio-renal | ||||||
| 10/21/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Respiratory | ||||||
| 10/09/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/10/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: Cardio-renal | ||||||
| 07/14/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/12/2021 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $32.95 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 07/12/2021 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| KF7013-04 | GRT US Holding, Inc. | $257,402 | 5 |
| A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder OAB Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms LUTS Due to Benign Prostatic Hyperplasia BPH | Astellas Pharma Global Development | $133,059 | 5 |
| DS5565-A-U307 | Daiichi Sankyo Inc. | $56,496 | 115 |
| ER/LA Opioid PMR Requirements Clinical Study | Collegium Pharmaceutical, Inc. | $49,253 | 4 |
| DS5565-A-E310 | Daiichi Sankyo Inc. | $35,734 | 104 |
| A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN MEN WITH OVERACTIVE BLADDER OAB SYMPTOMS WHILE TAKING THE ALPHA BLOCKER TAMSULOSIN HYDROCHLORIDE FOR LOWER URINARY TRACT SYMPTOMS LUTS DUE TO BENIGN PROSTATIC HYPERPLASIA BPH | Astellas Pharma Global Development | $9,200 | 1 |
| ER/LA Opioid PMR Requirements Clinical Study | Egalet US Inc | $4,881 | 5 |
| Opioid PMR Study | West-Ward Pharmaceuticals | $4,060 | 5 |
| ER/LA Opioid PMR Requirements Clinical Study | Purdue Pharma L.P. | $3,789 | 4 |
| DS5565-A-E312 | Daiichi Sankyo Inc. | $2,500 | 1 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms LUTS Due to Benign Prostatic Hyperplasia BPH | Astellas Pharma Global Development | $1,051 | 1 |
| A Randomized Double Blind Placebo-Controlled Clinical Trial of Structured Opioid Discontinuation Verses Continued Opioid Therapy in Suboptimal and Optimal Responders to High-Dose Long Term Opioid Analgesic therapy for Chronic Pain Protocol #3033-11 and 2065-5 | Purdue Pharma L.P. | $996.58 | 1 |
| OPC - 5 Investigator Meeting #2 for Protocol 2065-5 | Purdue Pharma L.P. | $841.67 | 1 |
| OPC - 5 Investigator Meeting #2 for Protocol 2065-5 | Collegium Pharmaceutical, Inc. | $776.92 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Structured Opioid Discontinuation Versus Continued Opioid Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioid Analgesic Therapy for Chronic Pain. | Endo Pharmaceuticals Inc. | $383.73 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 590 | 822 | $147,110 | $46,651 |
| 2022 | 8 | 573 | 785 | $109,498 | $40,028 |
| 2021 | 9 | 622 | 840 | $135,333 | $47,124 |
| 2020 | 10 | 725 | 970 | $170,738 | $55,034 |
Total Patients
2,510
Total Services
3,417
Medicare Billing
$188,836
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 148 | 249 | $66,840 | $16,742 | 25.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 113 | 113 | $35,595 | $16,231 | 45.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 36 | 36 | $23,400 | $6,122 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 33 | 36 | $11,460 | $3,635 | 31.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 152 | 262 | $1,965 | $1,911 | 97.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 91 | 106 | $4,770 | $1,129 | 23.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 17 | 20 | $3,080 | $880.22 | 28.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 128 | 128 | $40,270 | $18,648 | 46.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 99 | 163 | $32,600 | $10,993 | 33.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 26 | 27 | $17,550 | $4,172 | 23.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 20 | $5,900 | $2,168 | 36.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 35 | 44 | $5,280 | $1,897 | 35.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 96 | 111 | $4,995 | $1,096 | 21.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 159 | 277 | $2,078 | $820.47 | 39.5% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 14 | 15 | $825.00 | $233.63 | 28.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 104 | 104 | $32,760 | $15,475 | 47.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 100 | 159 | $31,800 | $10,177 | 32.0% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 59 | 61 | $39,650 | $10,113 | 25.5% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2021 | 20 | 20 | $8,900 | $3,758 | 42.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 26 | 32 | $9,440 | $3,498 | 37.1% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 28 | 35 | $4,200 | $1,502 | 35.8% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 98 | 119 | $5,355 | $1,325 | 24.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 171 | 291 | $2,183 | $873.00 | 40.0% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 16 | 19 | $1,045 | $402.99 | 38.6% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2020 | 84 | 87 | $56,550 | $14,722 | 26.0% |
About Dr. Alexander Ford, MD
Dr. Alexander Ford, MD is a Cardiovascular Disease healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699842849.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alexander Ford, MD has received a total of $563,203 in payments from pharmaceutical and medical device companies, with $77.16 received in 2024. These payments were reported across 338 transactions from 26 companies. The most common payment nature is "" ($560,424).
As a Medicare-enrolled provider, Ford has provided services to 2,510 Medicare beneficiaries, totaling 3,417 services with total Medicare billing of $188,836. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Los Angeles, CA
- Active Since 11/30/2006
- Last Updated 12/03/2008
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1699842849
Products in Payments
- Neridronic acid (Drug) $257,402
- MIRABEGRON (Drug) $134,110
- DS-5565 (Drug) $94,729
- MYRBETRIQ (Drug) $9,200
- Morphine Sulfate ER tablets (Drug) $2,457
- Oxymorphone hydrochloride ER tablet (Drug) $1,119
- OXYCODONE HYDROCHLORIDE (Drug) $996.58
- Xtampza ER (Drug) $776.92
- Oxycodone hydrochloride ER tablet (Drug) $484.20
- OPANA ER (Drug) $383.73
- FARXIGA (Drug) $273.86
- JARDIANCE (Drug) $178.92
- Prolia (Biological) $139.37
- XARELTO (Drug) $110.70
- ELIQUIS (Drug) $109.75
- JANUVIA (Drug) $89.46
- TRADJENTA (Drug) $76.85
- MOUNJARO (Drug) $74.32
- ENTRESTO (Drug) $68.09
- Repatha (Biological) $67.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Los Angeles
Dr. Leslie Saxon, M.d, M.D
Cardiovascular Disease — Payments: $1.6M
Cardiovascular Disease $1.6M
Dr. Cathleen Bairey Merz, M.d, M.D
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Ramin Ebrahimi, Md, MD
Cardiovascular Disease — Payments: $879,009
Cardiovascular Disease $879,009
Karol Watson, Md, MD
Cardiovascular Disease — Payments: $707,428
Cardiovascular Disease $707,428
Rahul Doshi, M.d, M.D
Cardiovascular Disease — Payments: $479,484
Cardiovascular Disease $479,484
Gregg Fonarow, Md, MD
Cardiovascular Disease — Payments: $461,238
Cardiovascular Disease $461,238